Genelux (GNLX) Interest & Investment Income (2023 - 2026)
Genelux (GNLX) posted quarterly Interest & Investment Income of $173000.0 for Q1 2026, down 5.98% year-over-year from $184000.0 in Q1 2025, and up 35.16% quarter-over-quarter from $128000.0 in Q4 2025.
Genelux (GNLX) Interest & Investment Income (2023 - 2026) Analysis & Trends
Genelux's Interest & Investment Income history runs 4 years deep, the most recent figure standing at $173000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 5.98% year-over-year to $173000.0; the TTM figure through Mar 2026 stood at $700000.0 (down 9.09% YoY), while the FY2025 annual figure was $711000.0, up 1.57% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $173000.0, up from $128000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $265000.0 in Q1 2024, with the low at $4000.0 in Q3 2023.
- The 4-year median for Interest & Investment Income is $184000.0 (2025), against an average of $179909.1.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income soared 5450.0% in 2024, then slumped 36.32% in 2025.
- Genelux's Interest & Investment Income stood at $240000.0 in 2023, then declined by 16.25% to $201000.0 in 2024, then plunged by 36.32% to $128000.0 in 2025, then surged by 35.16% to $173000.0 in 2026.
- Business Quant data shows GNLX's Interest & Investment Income at $173000.0 in Q1 2026, $128000.0 in Q4 2025, and $175000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | 173,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 173,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | 175,000.00 |
| Jun 30, 2025 | 224,000.00 |
| Mar 31, 2025 | 184,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 222,000.00 |
| Jun 30, 2024 | 163,000.00 |
| Mar 31, 2024 | 265,000.00 |
| Dec 31, 2023 | 240,000.00 |
| Sep 30, 2023 | 4,000.00 |